Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530255 | 1.00 | NPC1L1 (0.47) | NPC1L1ROCK2ROCK1ACACBGSK3A | |
| SCHEMBL5521333 | 1.00 | NPC1L1 (0.47) | NPC1L1ROCK2ROCK1ACACBGSK3A | |
| SCHEMBL5522286 | 0.88 | NPC1L1 (0.52) | NPC1L1ROCK2ROCK1ACACBHDAC3 | |
| SCHEMBL5522289 | 0.88 | NPC1L1 (0.52) | NPC1L1ROCK2ROCK1ACACBHDAC3 | |
| SCHEMBL4552782 | 0.78 | ROCK2 (0.51) | ROCK2ROCK1ACACB | |
| SCHEMBL5522737 | 0.77 | NPC1L1 (0.54) | NPC1L1ROCK2ROCK1ACACBHDAC3 | |
| SCHEMBL5522741 | 0.77 | NPC1L1 (0.54) | NPC1L1ROCK2ROCK1ACACBHDAC3 | |
| SCHEMBL8285570 | 0.77 | GSK3A (0.36) | GSK3AGSK3B | |
| SCHEMBL14425165 | 0.75 | HTR4 (0.55) | NPC1L1GSK3BHDAC3 | |
| SCHEMBL4882767 | 0.74 | ROCK2 (0.56) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | NPC1L1 2558/4885ROCK2 4012/4885ROCK1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.